Results 51 to 60 of about 6,254,499 (310)

Toxicological Analysis of Some Drugs of Abuse in Biological Samples [PDF]

open access: yes, 2015
Consumption of drugs of abuse is a scourge of modern world. Abuse, drug addiction and their consequences are one of the major current problems of European society because of the significant repercussions in individual, family, social and economic level ...
Baconi, Daniela Luiza   +5 more
core   +3 more sources

Biophysical analysis of angiotensin II and amyloid‐β cross‐interaction in aggregation and membrane disruption

open access: yesFEBS Letters, EarlyView.
Angiotensin II (AngII), a neuropeptide, interacts with amyloid‐β (Aβ), a key player in Alzheimer's disease. This study reveals that AngII reduces Aβ aggregation and membrane disruption in vitro. Biophysical assays and molecular modeling suggest AngII binds disordered Aβ forms, potentially modulating early amyloidogenic events and contributing to ...
Mohsen Habibnia   +5 more
wiley   +1 more source

Oxoammonium salts are catalysing efficient and selective halogenation of olefins, alkynes and aromatics

open access: yesNature Communications, 2021
Organohalides are widely used as synthetic precursors and target products, but for various halogenation reactions there is a need for effective catalysts to activate commercially available haleniums.
Weijin Wang   +6 more
doaj   +1 more source

Dataset on the phagocytic and oxidative capacity of monocytes and granulocytes in the combined therapy of S.aureus infection in mice

open access: yesData in Brief, 2023
The aim of this study was to evaluate phagocytic and oxidative activities of monocytes and granulocytes during combined therapy of mice infected by drug-resistant Staphylococcus aureus SCAID OTT1-2022.
Tamara A. Bukeyeva   +4 more
doaj   +1 more source

4‐nitrobenzoate inhibits 4‐hydroxybenzoate polyprenyltransferase in malaria parasites and enhances atovaquone efficacy

open access: yesFEBS Letters, EarlyView.
Atovaquone is an antimalarial requiring potentiation for sufficient efficacy. We pursued strategies to enhance its activity, showing that 4‐nitrobenzoate inhibits 4‐hydroxybenzoate polyprenyltransferase, decreasing ubiquinone biosynthesis. Since atovaquone competes with ubiquinol in mitochondria, 4‐nitrobenzoate facilitates its action, potentiating ...
Ignasi Bofill Verdaguer   +7 more
wiley   +1 more source

Carneusones A-F, Benzophenone Derivatives from Sponge-Derived Fungus Aspergillus carneus GXIMD00543

open access: yesMarine Drugs
Six benzophenone derivatives, carneusones A-F (1–6), along with seven known compounds (7–13) were isolated from a strain of sponge-derived marine fungus Aspergillus carneus GXIMD00543.
Chun-Ju Lu   +11 more
doaj   +1 more source

Development and Validation of a Method for the Quantitative Determination of Etoricoxib in Liquid Dosage Form

open access: yesРазработка и регистрация лекарственных средств, 2023
Introduction. Etoricoxib is a selective cyclooxygenase (COX-2) inhibitor used for the treatment of acute pain and has anti-inflammatory and analgesic efficacy. Etoricoxib causes fewer complications compared to other non-steroidal anti-inflammatory drugs (
A. Kh. Amandusova   +10 more
doaj   +1 more source

Organoids in pediatric cancer research

open access: yesFEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Examining catastrophic costs and benefit incidence of subsidized antiretroviral treatment (ART) programme in south-east Nigeria.

open access: yes, 2008
OBJECTIVES: To examine the extent to which costs of subsidized antiretrovirals treatment (ART) programmes are catastrophic and the benefit incidence that accrues to different population groups.
Chukwuka, Chinwe   +6 more
core   +1 more source

Silence of the limbs: pharmacological symptomatic treatment of intermittent claudication [PDF]

open access: yes, 2010
Several oral "vasoactive" drugs claim to increase walking capacity in patients with intermittent claudication (IC). Naftidrofuryl, cilostazol, buflomedil, and pentoxifylline are the most studied molecules.
De Backer, Gui   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy